Company intelligence / Profile preview

Omega Capital

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Omega Funds is a private healthcare venture capital firm focused on investing in innovative life sciences companies rather than operating its own drug development pipeline. Founded in 2004, the firm backs therapeutics and platform companies addressing severe unmet medical needs across areas such as oncology, immunology, rare diseases, and precision medicine. Omega Funds has offices in Boston and Geneva and announced the close of Omega Fund VIII at $647 million in July 2025. The firm presents itself as a specialist investor that supports founders, company creation, and growth of biotech businesses in the U.S. and Europe.

Industry: Investors

Beyond the preview

Go deeper on Omega Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omega Capital.

Explore the full profile